Medicine delivery company raises £1.2m

BIO-IMAGES Drug Delivery has raised a further £1.2 million as it responds to growth in demand.

The investment has been led by Edinburghbased business angel investment syndicate, Archangels, supported by Scottish Enterprise and Biocity Investments.

The funding will enable BDD to invest in senior hires and significantly expand its current good manufacturing practice capabilities to support product development, manufacture of clinical trial supplies and for rapid manufacture of products to support its clinical trials service.

The new manufacturing and formulation capabilities will allow international pharma, biotech and consumer health companies to speed up the clinical evaluation of their products, resulting in a reduction in development time and costs.

BDD, which is based in Glasgow and Newhouse Biocity Scotland, works with global companies outlicensing its proprietary Oralogik timed release technology, which enables the oral delivery of single, multidose or combination drugs at pre-determined times between one and 12 hours after being swallowed by the patient. Carol Thomson, BDD chief executive, said:

“This is a very exciting time for BDD. We have always been recognised for our ability to provide rapid development and clinical proof of performance for new drug products. This growth allows us to build on that, providing a single centre comprehensive service from development through in vivo testing and provision of larger scale clinical trial supplies.” Sarah Hardy, of Archangels, said: “BDD is a great example of homegrown innovation that is growing and diversifying its offering to respond to client needs, accelerating drug development.”